Immunoliposome targeting to mesangial cells: A promising strategy for specific drug delivery to the kidney

Journal of the American Society of Nephrology

Volumn 16, Issue 11, 2005, Pages 3295-3305

  Tuffin, Gérald ^a,d   Waelti, Ernst ^b   Huwyler, Jörg ^c   Hammer, Caroline ^b   Marti, Hans Peter ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d Unilabs Mittelland   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; IMMUNOLIPOSOME; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY OX7; UNCLASSIFIED DRUG; DRUG CARRIER; LIPOSOME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BINDING ASSAY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG FORMULATION; DRUG HALF LIFE; GLOMERULUS; KIDNEY DISEASE; LOW DRUG DOSE; MALE; MESANGIUM CELL; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; ANTIGEN PRESENTING CELL; CELL LINE; CHRONIC KIDNEY FAILURE; FLOW CYTOMETRY; KIDNEY; MESANGIUM; PATHOPHYSIOLOGY; PHYSIOLOGY; TRANSPORT AT THE CELLULAR LEVEL; WISTAR RAT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGEN-PRESENTING CELLS; BIOLOGICAL TRANSPORT; CELL LINE; DOXORUBICIN; DRUG CARRIERS; FLOW CYTOMETRY; GLOMERULAR MESANGIUM; KIDNEY; KIDNEY FAILURE, CHRONIC; LIPOSOMES; MALE; RATS; RATS, WISTAR;

EID: 33644873618     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2005050485     Document Type: Article

References (41)

1. US Renal data System: USRDS 2002 Annual Data Report, Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2003. Available: http://www.usrds.org/. Accessed September 7, 2005
2. Andrews PA: Renal transplantation. BMJ 324: 530-534, 2002
3. Donadio JV, Grande JP: IgA nephropathy. N Engl J Med 347: 738-748, 2002
4. Bokemeyer D, Ostendorf T, Kunter U, Lindemann M, Kramer HJ, Floege J: Differential activation of mitogen-activated protein kinases in experimental mesangioproliferative glomerulonephritis. J Am Soc Nephrol 11: 232-240, 2000
5. Ruggenenti P, Schieppati A, Remuzzi G: Progression, remission, regression of chronic renal diseases. Lancet 357: 1601-1608, 2001
6. Couser WG: Glomerulonephritis. Lancet 353: 1509-1515, 1999
7. Dillon JJ: Treating IgA nephropathy. J Am Soc Nephrol 12: 846-847, 2001
8. Ballardie FW, Roberts IS: Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J Am Soc Nephrol 13: 142-148, 2002
9. Pozzi C, Andrulli S, Del VL, Melis P, Fogazzi GB, Altieri P, Ponticelli C, Locatelli F: Corticosteroid effectiveness in IgA nephropathy: Long-term results of a randomized, controlled trial. J Am Soc Nephrol 15: 157-163, 2004
10. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D: Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 51: 691-743, 1999
11. Zhang Y, Boado RJ, Pardridge WM: In vivo knockdown of gene expression in brain cancer with intravenous RNAi in adult rats. J Gene Med 5: 1039-1045, 2003
12. Drummond DC, Zignani M, Leroux J: Current status of pH-sensitive liposomes in drug delivery. Prog Lipid Res 39: 409-460, 2000
13. Torchilin VP: Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 4: 145-160, 2005
14. Mastrobattista E, Koning GA, Storm G: Immunoliposomes for the targeted delivery of antitumor drugs. Adv Drug Deliv Rev 40: 103-127, 1999
15. Park JW, Kirpotin DB, Hong K, Shalaby R, Shao Y, Nielsen UB, Marks JD, Papahadjopoulos D, Benz CC: Tumor targeting using anti-her2 immunoliposomes. J Control Release 74: 95-113, 2001
16. Schnyder A, Krahenbuhl S, Torok M, Drewe J, Huwyler J: Targeting of skeletal muscle in vitro using biotinylated immunoliposomes. Biochem J 377: 61-67, 2004
17. Huwyler J, Wu D, Pardridge WM: Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci U S A 93: 14164-14169, 1996
18. Paul LC, Rennke HG, Milford EL, Carpenter CB: Thy-1.1 in glomeruli of rat kidneys. Kidney Int 25: 771-777, 1984
19. Waelti E, Wegmann N, Schwaninger R, Wetterwald A, Wingenfeld C, Rothen-Rutishauser B, Gimmi CD: Targeting her-2/neu with antirat Neu virosomes for cancer therapy. Cancer Res 62: 437-444, 2002
20. Foglieni C, Bragonzi A, Cortese M, Cantu L, Boletta A, Chiossone I, Soria MR, Monaco L: Glomerular filtration is required for transfection of proximal tubular cells in the rat kidney following injection of DNA complexes into the renal artery. Gene Ther 7: 279-285, 2000
21. Raats CJ, van den BJ, Bakker MA, Oppers-Walgreen B, Pisa BJ, Dijkman HB, Assmann KJ, Berden JH: Expression of agrin, dystroglycan, and utrophin in normal renal tissue and in experimental glomerulopathies. Am J Pathol 156: 1749-1765, 2000
22. Sheehan JP, Sheehan JM, Holmberg EG, Geisert EE, Helm GA: A horseradish peroxidase-light and electron microscopic study of immunoliposomes utilized for intracellular delivery to the rat striatum. Neurosci Lett 333: 212-216, 2002
23. Yagmurca M, Erdogan H, Iraz M, Songur A, Ucar M, Fadillioglu E: Caffeic acid phenethyl ester as a protective agent against doxorubicin nephrotoxicity in rats. Clin Chim Acta 348: 27-34, 2004
24. Jefferson JA, Johnson RJ: Experimental proliferative glomerulonephritis (the anti-Thy1.1 model). J Nephrol 12: 297-307, 1999
25. Saad SY, Najjar TA, Al-Rikabi AC: The preventive role of deferoxamine against acute doxorubicin-induced cardiac, renal and hepatic toxicity in rats. Pharmacol Res 43: 211-218, 2001
26. Sengoelge G, Perschl A, Ferrara I, Horl WH, Sunder-Plassmann G: Surface antigens of human mesangial cells: Impact of growth surface or IL-1alpha. Tissue Antigens 60: 383-395, 2002
27. Matsumura Y, Gotoh M, Muro K, Yamada Y, Shirao K, Shimada Y, Okuwa M, Matsumoto S, Miyata Y, Ohkura H, Chin K, Baba S, Yamao T, Kannami A, Takamatsu Y, Ito K, Takahashi K: Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. Ann Oncol 15: 517-525, 2004
28. Daniel C, Duffield J, Brunner T, Steinmann-Niggli K, Lods N, Marti HP: Matrix metalloproteinase inhibitors cause cell cycle arrest and apoptosis in glomerular mesangial cells. J Pharmacol Exp Ther 297: 57-68, 2001
29. Steinmann-Niggli K, Ziswiler R, Kung M, Marti HP: Inhibition of matrix metalloproteinases attenuates anti-Thy1.1 nephritis. J Am Soc Nephrol 9: 397-407, 1998
30. Park JW: Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res 4: 95-99, 2002
31. Boerman OC, Laverman P, Oyen WJ, Corstens FH, Storm G: Radiolabeled liposomes for scintigraphic imaging. Prog Lipid Res 39: 461-475, 2000
32. Boerman OC, Oyen WJ, Storm G, Corvo ML, Van BL, van der Meer JW, Corstens FH: Technetium-99m labelled liposomes to image experimental arthritis. Ann Rheum Dis 56: 369-373, 1997
33. Zhu C, Zhang Y, Zhang YF, Yi LJ, Boado RJ, Pardridge WM: Organ-specific expression of the lacZ gene controlled by the opsin promoter after intravenous gene administration in adult mice. J Gene Med 6: 906-912, 2004
34. Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N, Gerber HP, Kikkawa Y, Miner JH, Quaggin SE: Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 111: 707-716, 2003
35. Hertig A, Rondeau E: Plasminogen activator inhibitor type 1: The two faces of the same coin. Curr Opin Nephrol Hypertens 13: 39-44, 2004
36. Cunningham MA, Rondeau E, Chen X, Coughlin SR, Holdsworth SR, Tipping PG: Protease-activated receptor 1 mediates thrombin-dependent, cell-mediated renal inflamma-tion in crescentic glomerulonephritis. J Exp Med 191: 455-462, 2000
37. Ito K, Chen J, Asano T, Vaughan ED Jr, Poppas DP, Hayakawa M, Felsen D: Liposome-mediated gene therapy in the kidney. Hum Cell 17: 17-28, 2004
38. Tomita N, Kim JY, Gibbons GH, Zhang L, Kaneda Y, Stahl RA, Ogborn M, Venderville B, Morishita R, Baran D, Dzau VJ: Gene therapy with an E2F transcription factor decoy inhibits cell cycle progression in rat anti-Thy 1 glomerulonephritis. Int J Mol Med 13: 629-636, 2004
39. Tomita N, Morishita R, Yamamoto K, Higaki J, Dzau VJ, Ogihara T, Kaneda Y: Targeted gene therapy for rat glomerulonephritis using HVJ-immunoliposomes. J Gene Med 4: 527-535, 2002
40. Schwaninger R, Waelti E, Zajac P, Wetterwald A, Mueller D, Gimmi CD: Virosomes as new carrier system for cancer vaccines. Cancer Immunol Immunother 53: 1005-1017, 2004
41. Zhang YF, Boado RJ, Pardridge WM: Absence of toxicity of chronic weekly intravenous gene therapy with pegylated immunoliposomes. Pharm Res 20: 1779-1785, 2003